Spero Therapeutics Reports Q2 2026 Loss, FDA Approval of Utebzi

EarningsCorporate Action

โดย GuruFocus·

Summary · why it matters

Spero Therapeutics reported a net loss of $9.6 million for the second quarter of 2026, compared to a net loss of $1.7 million in the same period last year, while highlighting the FDA approval of its antibiotic Utebzi. The company recorded no revenue in the quarter, down from $14.2 million a year earlier, as prior collaboration revenue from Pfizer and GSK was fully realized. Research and development expenses fell to $3.4 million from $10.7 million due to reduced clinical activity, while general and administrative expenses rose to $6.5 million from $5.9 million. Spero also announced it closed a $105 million non-dilutive, non-recourse royalty financing with Healthcare Royalty, extending its cash runway into the second half of 2029. The company said the FDA approved Utebzi on June 17, 2026, for complicated urinary tract infections, making it the first oral carbapenem approved in the US, with GSK holding exclusive commercialization rights worldwide excluding certain Asian territories.